The India flu diagnostic and treatment market is projected to grow at a CAGR of 8.61% throughout the forecast period. The market was valued at US$415.514 million in the year 2020 and is expected to reach a size of US$740.673 million by 2027.
The flu diagnostic and treatment market in India is poised to surge at a notable CAGR on account of the rapidly rising incidence of influenza throughout the country. Furthermore, the growing investments in the field of influenza treatment, especially among the high-risk population, which primarily includes pregnant women, infants, and the aged population, are some of the key factors bolstering the flu diagnostic and treatment market growth in the country during the next five years. Furthermore, the market in India is also projected to grow at a significant rate due to the lack of proper vaccination policy policies particularly focusing on influenza, which is anticipated to drive the demand for flu diagnostic and treatment solutions in the coming years. Apart from Mission Indradhanush, the country does not have any seasonal influenza vaccination/immunization policy.
However, the market growth for flu diagnostics and treatment in India may be restrained by the fact that there is a large proportion of the population without access to proper healthcare services. In addition, the lack of a sufficient number of influenza test labs is also hindering the market growth of flu diagnostics and treatment in India. Moreover, the increasing number of influenza cases in the country is also projected to bolster the growth of the flu diagnostic and treatment market growth during the forecast period and beyond. For instance, According to the NCDC (National Centre for Disease Control) statistics, the total cases of influenza in India surged from 525 in 2013 to 28,798 in 2019.
The type of flu, products offered, age group, and end-user are the segments used to divide up the Indian flu and diagnostics market. On the basis of the type of flu, the market has been classified on the basis of type A and type B. TAs the most prevalent type of influenza detected in the nation, type A is predicted to have a sizable share of the diagnostic and treatment market in India. By providing, the market has been divided into therapeutics and diagnostics. By age group the market has been segmented on the basis of the age groups of 0-14 years, 15-64 years, and >=65 years. The >=65 age group is projected to hold a notable share during the next five years as there is a continuous increase in the geriatric population in India. The segmentation has been carried out by the end-user based on hospital laboratories, outpatient clinics, and reference laboratories.
The coronavirus pandemic positively impacted the market. the robust outbreak of the virus and its exponential spread alerted authorities and resulted in the implementation of numerous containment measures. Regular flu checkups and treatment were one of the crucial measures adopted by the authorities, which nudge growth in the market.
Key Developments
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Report Metric | Details |
| Market Size Value in 2020 | US$415.514 million |
| Market Size Value in 2027 | US$740.673 million |
| Growth Rate | CAGR of 8.61% from 2020 to 2027 |
| Base Year | 2020 |
| Forecast Period | 2022–2027 |
| Forecast Unit (Value) | USD Million |
| Segments Covered | Type of Flu, Offering, Age Group, And End-User |
| Companies Covered | Abbott, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., 3M, BD |
| Customization Scope | Free report customization with purchase |
Key Market Segmentation